Duckworth Samantha E, Druelles Sophie, Brouwer Emily, Brown David A, Hakkarainen Katja M, Guleria Sonia
Epidemiology & Real-World Science, Parexel, Madrid, Spain.
Epidemiology & Real-World Science, Parexel, Paris, France.
Drug Saf. 2025 Apr;48(4):415-423. doi: 10.1007/s40264-024-01504-7. Epub 2024 Dec 17.
The Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) checklist is endorsed by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and is tailored for studies assessing Risk Minimisation Measures and Risk Evaluation and Mitigation Strategy (RMM/REMS) effectiveness; however, its awareness and usage remain unknown. We evaluated the implementation of the RIMES checklist in RMM/REMS effectiveness studies registered in the EUPAS register during 01 December 2017- 01 January 2024. Furthermore, the awareness and utilization of the RIMES checklist among researchers conducting RMM/REMS effectiveness studies was assessed.
The European Union Post-Authorisation Study (EUPAS) Register was reviewed to identify studies conducted in at least one European country within the specified timeframe. Data were extracted from the online EUPAS registrations, including uploaded study documents. Additionally, a survey was distributed through at International Society of Pharmacoepidemiology (ISPE) to assess awareness and checklist utilisation among researchers. Findings from both the review and the survey were reported descriptively.
Among 44 studies included in the review, cross-sectional questionnaire-based surveys (n = 28, 64%), and retrospective cohort studies using secondary data (n = 13, 30%) were frequently used study designs. Oncology (n = 12, 27%) and pregnancy-related conditions (n = 7, 16%) were frequently reported therapeutic areas. Most studies were required by regulators and typically evaluated the additional RMM/REMS. The awareness and usage of the RIMES checklist was low, while the ENCePP checklist was used frequently. Some researchers considered the ENCePP checklist adequate for RMM/REMS studies, while few advocated for the RIMES checklist.
The awareness and utilisation of the specific RIMES checklist designed for studies evaluating RMM/REMS was limited, indicating a need for improving awareness and utilisation of RIMES and harmonisation of existing guidance and frameworks for RMM/REMS effectiveness studies.
用于药物风险最小化评估研究(RIMES)的报告建议清单已得到欧洲药物流行病学和药物警戒中心网络(ENCePP)的认可,并且是为评估风险最小化措施及风险评估与缓解策略(RMM/REMS)有效性的研究量身定制的;然而,其认知度和使用情况仍不为人所知。我们评估了RIMES清单在2017年12月1日至2024年1月1日期间在EUPAS登记处登记的RMM/REMS有效性研究中的实施情况。此外,还评估了开展RMM/REMS有效性研究的研究人员对RIMES清单的认知度和使用情况。
对欧盟上市后研究(EUPAS)登记处进行审查,以确定在指定时间范围内至少在一个欧洲国家开展的研究。从在线EUPAS登记信息中提取数据,包括上传的研究文件。此外,通过国际药物流行病学学会(ISPE)开展了一项调查,以评估研究人员的认知度和清单使用情况。对审查和调查的结果进行了描述性报告。
在审查纳入的44项研究中,基于横断面问卷调查的研究(n = 28,64%)以及使用二手数据的回顾性队列研究(n = 13,30%)是常用的研究设计。肿瘤学(n = 12,27%)和妊娠相关病症(n = 7,16%)是经常报告的治疗领域。大多数研究是监管机构要求开展的,通常评估额外的RMM/REMS。RIMES清单的认知度和使用率较低,而ENCePP清单的使用较为频繁。一些研究人员认为ENCePP清单适用于RMM/REMS研究,而很少有人支持使用RIMES清单。
专为评估RMM/REMS的研究设计的特定RIMES清单的认知度和使用率有限,这表明需要提高对RIMES的认知度和使用率,并统一现有的RMM/REMS有效性研究指南和框架。